Search
AnaptysBio Inc
ANABAdd to Watchlist
59.663USD
+1.183+2.02%
Market hours （ET）Quotes delayed by 15 min
1.65BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-24The current earnings forecast score of AnaptysBio Inc is 8.73, ranking 69 out of 388 in the Biotechnology & Medical Research industry. The average price target is 62.50, with a high of 100.00 and a low of 20.00.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
88.800
Target Price
+54.41%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
AnaptysBio Inc
ANAB
11
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
CRISPR Therapeutics AG
CRSP
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is AnaptysBio Inc's expected revenue for the next quarter?
AnaptysBio Inc's expected revenue is 30.66M.
What is AnaptysBio Inc's price target?
Analysts forecast that AnaptysBio Inc's price target is USD 62.50, with the highest forecast at USD 100.00 and the lowest forecast at USD 20.00.
How have AnaptysBio IncANAB's recent earnings per share performed?
The market expectation was USD -1.84, while AnaptysBio IncANAB's earnings per share (EPS) for the previous quarter was USD -0.46. EPS for the next quarter is expected at USD -0.11.
What is the analyst rating for AnaptysBio Inc?
Based on the ratings of AnaptysBio Inc's stock from 11 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
